Telomir Pharmaceuticals announces two milestone for Telomir-1

Telomir Pharmaceuticals announced the commencement of several significant milestones. These events underscore its commitment to advancing innovative treatments to mitigate the effects of aging and the continuation of its groundbreaking work. “Beginning the telomere length and safety study, it is incredibly important for Telomir as it marks the next phase in the development of Telomir-1 and we believe should provide us with information that will help us to make progress in our efforts to combat many of the diseases of aging,” said Dr. Chris Chapman, Co-Founder, Chairman, CEO, President and CMO of Telomir. These studies are potentially usable for veterinary as well as human IND purposes. “We believe the data from the canine study will provide us with pre-clinical animal testing endpoints to determine Telomir-1’s potential as a treatment for age-related conditions such as gait weakness and joint damage, and will provide us with information on physical examinations, blood collection, urine collection, and telomere length.” Dr. Mike Roizen, special consultant to Telomir reiterated that “the study should not only be used to support further work on benefits and risks in canines, especially those with joint disease, but also provide key information for designing studies in humans.”